Three-Tier Investment Structure for the Healing Spider Platform Tier 1: Joint Irrigation, Joint Drug Delivery, Surgical Site Infection Mitigation Patent Basis: US 11,141,528 B1 Regulatory Strategy: 510(k) Investment Target: ~$5M (±15%) Description Tier 1 is built on the cartridge and fluid-delivery patent (US 11,141,528 B1), which covers: ● Joint irrigation ● Joint drug delivery ● SSI mitigation adjunct ● Programmable reservoirs and cartridge-based sterile fluid paths ● Controlled inlet/outlet flow ● Modular wet-path architecture It does not include stem-cell therapy, closed-loop biologic recirculation, or PDT. TAM Estimate (U.S.) ● Arthroscopy + orthopedic surgery: 2.4–3.1M procedures ● Drug delivery into joints: ~$4B ● Surgical irrigation and lavage: ~$1.2B ● SSI prophylaxis: ~$900M Tier 1 TAM Range: $4.5B–$6.0B per year Value Proposition ● Fastest regulatory pathway ● Immediately clinically useful ● Provides the hardware baseline for Tier 2 and Tier 3 ● Establishes the disposable cartridge recurring revenue channel Tier 2: Stem Cell / Orthobiologic Delivery + Closed/Open Loop System Patent Basis: US 10,864,321 B1 + US 11,141,528 B1 Regulatory Strategy: 510(k) hardware + De Novo for therapy environment Investment Target: ~$10M (±15%) Description Tier 2 expands to the full closed-loop biologic therapy environment: ● Stem cell delivery ● PRP and orthobiologic infusion ● Closed-loop recirculation ● Real-time flow and pressure monitoring ● Programmable infusion and dwell times ● Biologic-compatible disposable cartridges TAM Estimate (U.S.) ● Orthobiologics: ~$6B ● Stem cell therapy (sports + ortho): ~$2.5B ● Regenerative joint-disease therapies: ~$7.2B Tier 2 TAM Range: $12B–$16B per year Value Proposition ● Captures the highest-growth segment in orthopedics ● Offers recurring consumables revenue ● Enables multi-session therapeutic treatment plans ● Begins bridging from surgery into regenerative medicine Tier 3: PDT-Enabled Therapeutic Platform Patent Basis: US 10,864,321 B1 + US 11,141,528 B1 Regulatory Strategy: 510(k) hardware + PMA for PDT therapeutic claims Investment Target: ~$15M (±15%) Description Tier 3 is the complete closed-loop biological and photonic therapy system: ● All Tier 2 functionality ● Photodynamic therapy (PDT) applied directly to circulating therapeutic fluids ● Activation of photosensitized drug agents ● Enhanced cell viability, pathogen reduction, and inflammation modulation ● Potential breakthrough-device designation ● Zero direct competition in its category TAM Estimate (U.S.) ● Chronic inflammatory and degenerative joint disease: ~$5.3B ● PDT/photobiomodulation therapeutic markets: ~$1.2B ● High-value PDT-enhanced biologic therapy cycles: ~$3.5B–$4B Tier 3 TAM Range: $14B–$20B per year Value Proposition ● Clinically differentiated platform ● High-margin therapy category ● Creates entirely new care pathways ● Strongest long-term licensing and acquisition potential FDA Pathways and Timelines What Investors Should Expect FDA Approval Pathways 510(k) Clearance ● Used when a predicate exists ● Fastest and least expensive ● Tier 1 and mechanical hardware for Tiers 2 and 3 ● Timeline: 12–18 months De Novo Classification ● Moderate-risk devices with no predicate ● Most appropriate for Tier 2 closed-loop biologic environments ● Establishes a new product classification ● Timeline: 18–30 months PMA (Premarket Approval) ● Highest clinical burden ● Required for photodynamic therapeutic claims in Tier 3 ● Timeline: 36–56 months Tier-by-Tier Regulatory Overview Tier 1 ● Path: 510(k) ● Timeline: 12–18 months ● Budget: $5M ±15% (Range: $4.25M–$5.75M) Tier 2 ● Path: 510(k) for structural hardware ● De Novo for biologic-compatible closed-loop therapy ● Timeline: 24–36 months ● Budget: $10M ±15% (Range: $8.5M–$11.5M) Tier 3 ● Path: 510(k) for mechanical system ● PMA for PDT therapeutic claims ● Timeline: 36–56 months ● Budget: $15M ±15% (Range: $12.75M–$17.25M) Appendix CBER (Center for Biologics Evaluation and Research): Responsible for evaluating biologics, stem cells, and regenerative medicine products. CDRH (Center for Devices and Radiological Health): Responsible for devices, pumps, reservoirs, PDT light sources, and mechanical systems. *Tier 2 and Tier 3 will likely be handled as combination products, requiring coordinated review between the two centers. |